Ignyta Announces Entrectinib Phase 1 Data Presentation at the 2015 European Cancer Congress

Ignyta, Inc. RXDX, a precision oncology biotechnology company, today announced that a late-breaker abstract was selected for an oral presentation at the 2015 European Cancer Congress (ECC) in Vienna, Austria. The oral presentation relates to updated results of Phase 1 clinical trials of entrectinib, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to NTRK1, NTRK2, NTRK3, ROS1 or ALK, and will be held on Sunday, September 27, 2015. "We are honored that the ECC 2015 Scientific Program Committee has selected our late breaker abstract for an oral presentation session," said Pratik Multani, M.D., Chief Medical Officer of Ignyta. "We are looking forward to sharing updated data from our two Phase 1 clinical trials of entrectinib in this prestigious forum, and to discussing our entrectinib data and plans with key scientific and clinical experts." Details of the presentation are as follows: Date/time: Sunday, September 27, 2015, 5:20 PM, Vienna time Title: Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements. (Abstract number 29LBA) Presenter: Salvatore Siena, M.D., Director, Niguarda Hospital Cancer Center, Milan, Italy